Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

Citation data:

Bone, ISSN: 1873-2763, Vol: 105, Page: 11-17

Publication Year:
2017
Usage 39
Abstract Views 37
Link-outs 2
Captures 50
Readers 49
Exports-Saves 1
Social Media 78
Tweets 66
Shares, Likes & Comments 12
Citations 14
Citation Indexes 14
PMID:
28789921
DOI:
10.1016/j.bone.2017.08.003
Author(s):
Tsourdi, Elena; Langdahl, Bente; Cohen-Solal, Martine; Aubry-Rozier, Bérengere; Eriksen, Erik Fink; Guañabens, Nuria; Obermayer-Pietsch, Barbara; Ralston, Stuart H; Eastell, Richard; Zillikens, M Carola
Publisher(s):
Elsevier BV
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
review description
The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is not suppressed after its cessation. Recent reports imply that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures.